News | April 07, 2015

WMIS to Collaborate with NCI on Expansion of Co-Clinical Trials

WMIS hails President Obama’s emphasis on precision medicine and expansion of research to speed discovery

April 7, 2015 — The World Molecular Imaging Society (WMIS) announced the kick-off of a collaboration with the National Cancer Institute (NCI) to promote best practices for co-clinical trials. The goal of the collaboration is to speed the discovery of more and better treatments for cancer and other diseases. NCI is part of the National Institutes of Health (NIH).

WMIS also lauded President Obama’s recent announcement of the Precision Medicine Initiative designed “to bring us closer to curing diseases like cancer and diabetes?—?and to give all of us access to the personalized information we need to keep ourselves and our families healthier,” stated Jason Lewis, M.D., professor and vice chair for research, Emily Tow Jackson Chair at Memorial Sloan-Kettering Cancer Center, and president of the WMIS.

Over the past two years, WMIS and the American Association of Physicists in Medicine (AAPM) have shared their interest with NCI to promote best practices for co-clinical trials. The organizations met at the World Molecular Imaging Congress in September 2014 to finalize an agreement that WMIS, with the assistance of the AAPM, would explore how to promote best practice for quantitative imaging for co-clinical trials.

Co-clinical trials are defined as parallel or sequential trials of combination therapy in patients and in mouse and human-in-mouse models of appropriate genotypes to represent the patients. The initiative is designed to help establish best practices for quantitative imaging methods and imaging protocols that are applied to both mouse and human-in-mouse models. The research resources are expected to improve the correlation of results from mouse models with prospective and/or retrospective clinical trial data. The clinical goals are to support effective mouse/human co-clinic therapy and prevention trials.

Molecular imaging and the emerging field of theranostics are essential to the successful implementation of precision medicine. The World Molecular Imaging Society, with its international forum for discussing all aspects of molecular imaging and related fields, is in a unique position to take the lead in global discussion, innovation and scientific collaboration, from preclinical studies to first-in-human imaging trials,” said Hedvig Hricak M.D., Ph.D., chairman, Department of Radiology, Memorial Sloan-Kettering Cancer, and member of WMIS.

As part of the agreement, WMIS will include two spotlight sessions on precision medicine and co-clinical trials during the upcoming 8th Annual World Molecular Imaging Congress. The theme of the meeting is “Precision Medicine, Visualized,” which embodies current and future roles of molecular imaging in basic science, translational medicine and healthcare. The WMIC meeting will take place Sept. 2-5, 2015, in Honolulu, Hawaii.

“The WMIS is committed to bringing key technologies that enable the study of biology in the complexity of living systems to the greater scientific community, and to advancing the imaging tools that will help patients who suffer from the most devastating diseases. Our key focus for 2015 is precision medicine and disseminating knowledge, new tools and technologies that help expand the development of this theme on a global scale is the aim of WMIS and we work with our international colleagues to ensure that our voice reflects the advances taking place around the world,” added Lewis.

For more information:

Related Content

ASTRO Issues Clinical Guideline for Whole Breast Radiation Therapy
News | Radiation Therapy | March 12, 2018
The American Society for Radiation Oncology (ASTRO) today issued a new clinical guideline for the use of whole breast...
The yellow in the anterolateral entorhinal cortex of the young brain indicates significant activity, something that is absent in the older brain.

This figure shows two different brains that are aligned to a common template space for comparison. The yellow in the anterolateral entorhinal cortex of the young brain indicates significant activity, something that is absent in the older brain. CREDIT: Zachariah Reagh

News | Nuclear Imaging | March 08, 2018
As we get older, it's not uncommon to experience "senior moments," in which we forget where we parked our car or call...
MD Anderson and RaySearch Partner to Advance Adaptive Radiation Therapy
News | Treatment Planning | February 26, 2018
The University of Texas MD Anderson Cancer Center and RaySearch Laboratories announced a new strategic alliance with...
Mirada Medical Releases DLCExpert for Radiotherapy Treatment Planning
Technology | Treatment Planning | February 22, 2018
February 22, 2018 — U.K.-based medical imaging software provider Mirada Medical has released DLCExpert, the first com
Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...
Mitchell Cancer Institute Selects RayStation for TomoTherapy Planning
News | Treatment Planning | February 16, 2018
The University of South Alabama Mitchell Cancer Institute (MCI) in Mobile, Ala., has selected RayStation as its...
Radiography Education Enrollment Shows Marginal Rise in 2017
News | Business | February 15, 2018
Directors of radiography educational programs report the number of enrolled students increased slightly in 2017, while...
A Tc99m SPECT cardiac exam showing myocardial perfusion in the heart.

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Feature | Radiopharmaceuticals and Tracers | February 08, 2018 | Dave Fornell
February 8, 2018 — The U.S.
Varian Acquires Mobius Medical Systems
News | Quality Assurance (QA) | February 06, 2018
February 6, 2018 – Varian announced it has acquired privately-held Mobius Medical Systems, a...
Overlay Init